Journal of the European Academy of Dermatology and Venereology : JEADV
-
J Eur Acad Dermatol Venereol · Jun 2016
HiSCR (Hidradenitis Suppurativa Clinical Response): a novel clinical endpoint to evaluate therapeutic outcomes in patients with hidradenitis suppurativa from the placebo-controlled portion of a phase 2 adalimumab study.
Determining treatment response for patients with hidradenitis suppurativa (HS) can be challenging due to limitations of current disease activity evaluations. ⋯ HiSCR was more responsive to change than HS-PGA Response in this subpopulation.